Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...

Nektar Therapeutics is advancing Rezpeg in atopic dermatitis and alopecia areata. Click here for key insights on NKTR's ...

Nektar Therapeutics has announced top-line results from its trial of rezpegaldesleukin to treat severe to very severe ...

Absci Corporation (NASDAQ:ABSI) is one of the best multibagger penny stocks to buy right now. On December 12, Needham’s Gil ...

A debate over public funding for hair-loss treatment has intensified after President Lee Jae Myung ordered officials to ...

Despite falling short of its primary Phase II objective, Nektar plans to push its T cell stimulator rezpeg into Phase III ...

A treatment for alopecia areata could move forward despite a setback in a midstage clinical trial.

Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...

Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before ...

Clascoterone 5%, a topical anti-androgen drug indicated for male pattern hair loss, demonstrated significant hair regrowth ...

Nektar Therapeutics released data from a study of its rezpegaldesleukin drug, establishing proof-of-concept in patients with severe to very severe alopecia areata, a hair-loss condition.

Many conditions, as well as genetics, can cause hair loss and balding. Find out how nutrient deficiencies, hormonal changes, ...